Kura Oncology is trading 5.05% lower at $9.87; no clear company-specific news was found to explain the decline. - The October 13 announcement concerns a planned 4:30 p.m. ET webcast with Caspian Therapeutics about KO-7246’s development strategy; it does not report or explain the share-price decline. - Biotech shares are also under pressure, with XBI down 2.01%. Sector weakness may be contributing, but no direct cause has been established.